Avant Proteins to exit SG as director cites inability to pay debts

The group declared it is unable to continue due to liabilities.

Avant Proteins Pte. Ltd. has declared that it is unable to continue its business due to its liabilities, according to a notice published in Singapore’s Government Gazette on 29 January.

In a statutory declaration made under the ‘Insolvency, Restructuring and Dissolution Act 2018’, director Chan Kai Yi Carrie said that the company “cannot, by reason of its liabilities, continue its business.”

The declaration was made on 26 January. Meetings of the company and its creditors have been scheduled for 13 February 2026.

Separately, Avant Proteins will transition its operations out of Singapore, the group said in a LinkedIn post.

The company established its Singapore presence in 2021 through a project with the A*STAR Bioprocessing Technology Institute at Biopolis and later operated a pilot facility in Woodlands.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia